News and Announcements
Yale Hematolgy Leader Joins Prescient Therapeutics Scientific Advisory Board
- Published January 14, 2016 11:19AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
14th January 2016, ASX Announcement
Clinical stage oncology company Prescient Therapeutics Ltd (PTX) has appointed a highly respected US-based specialist in myeloid malignancies Dr Thomas Prebet MD, PhD of Yale Cancer Center to the PTX Scientific Advisory Board (SAB).
Dr Prebet is the Assistant Director of Myeloid Malignancy Research at Yale, where he is looking to expand the clinical and translational research program in myeloid malignancies.
Dr Prebet was previously with the Insitiut Paoli-Calmettes in Marseille France where he was an Associate Professor of Clinical Hematology and a member of the molecular pharmacology group, as well as the early phase trial group and coordiniator of the leukemia ward.
To read the full announcement, please click here.